She had her life back.
For two decades, patients with platinum-resistant ovarian cancer faced a narrowing corridor of options — enduring treatments that extended life while diminishing its texture. Now, the NHS has approved mirvetuximab soravtansine, a drug that works not by flooding the body with toxicity but by guiding a lethal payload directly to cancer cells that carry a specific molecular signature. For up to 400 patients a year in England, this marks not merely a clinical advance but a restoration — of months, of energy, of ordinary life.
- Women with chemotherapy-resistant ovarian cancer have spent years facing a brutal arithmetic: treatments that bought time but stripped away the quality of the life being saved.
- Mirvetuximab breaks that equation by acting as a biological missile, fusing a chemotherapy agent to an antibody engineered to seek out cancer cells and spare the rest of the body.
- Clinical trials showed survival extending from 12.8 to 16.5 months, but the more urgent finding was that patients kept their hair, their energy, and their ability to live — not just endure.
- NHS approval now makes this the first new treatment for this form of ovarian cancer in 20 years, though access is limited to the 30–40% of resistant cases carrying the folate receptor alpha marker.
- Clinicians, charity leaders, and patients are calling it the most significant breakthrough in hard-to-treat ovarian cancer in a generation — a moment long overdue for those who had run out of road.
Patricia Hill was 64 when she began taking mirvetuximab soravtansine in January of this year, after years of conventional chemotherapy had kept her alive but left her hollowed out. Within weeks, she told the BBC, the difference was stark — she was visiting family in Ireland, attending shows in London's West End, going to the Chelsea Flower Show. She had, in her own telling, her life back.
The drug works by engineering antibodies to seek out a specific marking — folate receptor alpha — found on the surface of certain ovarian cancer cells. Once the antibody locks on and is absorbed, it releases a chemotherapy agent directly inside the cell. Researchers call it a "Trojan horse" approach: the cancer welcomes what ultimately destroys it, while the rest of the body is largely left unharmed. Patients on the drug keep their hair, experience less fatigue and nausea, and receive infusions every three weeks rather than every week.
The survival data is meaningful — average survival extended from 12.8 to 16.5 months — but clinicians emphasise that the quality of those extra months is what sets this drug apart. Jenny Green, 71, who participated in the clinical trials, reported minimal side effects and watched her cancer nodules shrink on successive scans.
The NHS has now approved the drug for ovarian, peritoneal, and fallopian tube cancers resistant to platinum-based chemotherapy, provided the cancer cells carry the relevant genetic marker — a condition met in roughly 30 to 40 percent of resistant cases. Up to 400 patients a year in England stand to benefit. Dr. Rowan Miller, who led the trials at University College London Hospital, described the approval as the culmination of a 20-year search. Prof Ruth Plummer called it the most significant breakthrough in this disease category in over two decades.
Developed by AbbVie and funded by NHS England, the drug's arrival closes a long gap in treatment options for one of the hardest cancers to treat. For patients like Patricia Hill, the policy milestone translates into something more immediate: the chance to live, for a while longer, as themselves.
Patricia Hill was diagnosed with ovarian cancer in 2023, and like most patients with her condition, she endured multiple rounds of conventional chemotherapy. The treatment worked, but it came at a cost—the kind of cost that doesn't show up in survival statistics. She was exhausted. She was sick. The life she had before cancer became something she could only remember, not live. Then in January of this year, at 64, she started taking a new drug called mirvetuximab soravtansine. Within weeks, she told the BBC, it felt like night and day. She could visit family in Ireland. She could see shows in London's West End. She could go to restaurants, attend the Chelsea Flower Show. She had her life back.
Mirvetuximab is what researchers call a "biological missile"—a piece of advanced chemistry that works like nothing that came before it. The drug is made by fusing a deadly chemotherapy agent to an antibody, the kind of protein the body naturally uses to fight infection. But these antibodies have been engineered to recognize a specific marking called folate receptor alpha, which appears on the surface of some ovarian cancer cells. When the drug enters the bloodstream, the antibodies hunt for those markings, stick to them, and get absorbed into the cancer cells. Once inside, they release their toxic payload. The cancer dies. The rest of the body is largely spared. It's a form of what researchers also call "Trojan horse" therapy—the medicine sneaks past the body's defenses by disguising itself as something the cancer recognizes and welcomes.
The numbers tell part of the story. Patients on conventional chemotherapy survived an average of 12.8 months. Patients on mirvetuximab survived 16.5 months—a gain of nearly four months. But the real measure of this drug's impact lies in what those extra months feel like. Women on mirvetuximab keep their hair. They don't feel as tired or as sick. The infusions come every three weeks instead of every week. Jenny Green, 71, was part of the clinical trials that proved the drug worked. She reported hardly any side effects at all, and scans showed her cancer nodules shrinking. "My bloods were coming back into range," she said. "Which is all pretty good to hear."
The NHS has now approved mirvetuximab for ovarian, peritoneal, and fallopian tube cancers that no longer respond to chemotherapy and carry the right genetic markings. Up to 400 patients a year in England could benefit—the first new treatment for this hard-to-treat form of ovarian cancer to reach the NHS in two decades. There are nearly 7,750 cases of ovarian cancer diagnosed in the UK each year, and for those whose cancers become resistant to platinum-based chemotherapy, options have been brutally limited. About 30 to 40 percent of chemotherapy-resistant cancers carry the folate receptor alpha markings that make them vulnerable to this new drug.
Dr. Rowan Miller, who ran the clinical trials at University College London Hospital, said she was "really excited" to see mirvetuximab reach the NHS after a 20-year search for better medications. "Finally, there's a drug that's available, that improves survival for this group of patients and in addition, the patients get on with the treatment well and find it easier to manage than standard chemotherapy," she said. Prof Ruth Plummer, the NHS national clinical lead for cancer drugs, called it the "most significant breakthrough" in treating hard-to-treat ovarian cancers in over two decades. Victoria Clare, chief executive of Ovacome, the UK's ovarian cancer support charity, said the decision had the potential to make a real difference for those able to access it. Rachel Downing, head of policy at Target Ovarian Cancer, called it "a hugely important moment" for women with platinum-resistant ovarian cancer and their families, "who have faced limited effective treatment options for far too long."
The drug was developed by the pharmaceutical company AbbVie. NHS England will pay for it. Wales and Northern Ireland typically follow the same rules, though Scotland makes its own decisions. For Patricia Hill and the hundreds of patients who will follow her, the approval means something simpler than policy or statistics: it means the possibility of a life that looks, for a while longer, like the one they had before.
Notable Quotes
The difference was like night and day, and the therapy had given her a lot of her life back.— Patricia Hill, 64, ovarian cancer patient
Finally, there's a drug that's available, that improves survival for this group of patients and in addition, the patients get on with the treatment well and find it easier to manage than standard chemotherapy.— Dr. Rowan Miller, UCLH clinical trials lead
The Hearth Conversation Another angle on the story
Why does this drug work so differently from standard chemotherapy?
It's about precision. Standard chemotherapy is like dropping poison everywhere in the body and hoping the cancer dies before the patient does. This drug uses antibodies—the body's own recognition system—to find cancer cells specifically and deliver the poison directly to them. The cancer cells have a marking on their surface that normal cells don't have, and the antibodies lock onto it.
So the side effects are better because less of the body is being poisoned?
Exactly. You're not destroying healthy cells at the same rate. Women keep their hair. They don't feel as exhausted or nauseated. They can actually live their lives while being treated, not just survive the treatment itself.
But it doesn't work for everyone?
Only about 30 to 40 percent of chemotherapy-resistant ovarian cancers have the right marking. For those patients, it's transformative. For the others, it's not an option. That's the limitation.
Four months of extra survival—is that significant?
In absolute terms, yes. But listen to what Patricia Hill said: she could go to the theatre, visit family, eat at restaurants. Those four months aren't just time; they're quality. They're her life back.
Why did it take 20 years to get here?
Developing a drug that can recognize cancer cells and deliver poison to them without harming the body is extraordinarily difficult. You have to understand the biology, engineer the antibodies, test it, prove it works. Twenty years is actually fast for something this complex.
What happens to patients whose cancers don't have the marking?
They're back where they started—with very limited options. That's why this approval matters so much. For the first time in two decades, there's a new tool. It won't help everyone, but for those it does help, it changes everything.